Tarceva Gets Thumbs Down For NSCLC: Cmte. Seeks Better Subgroup Analysis

The Oncologic Drugs Advisory Committee's rejection of OSI Pharmaceutical's Tarceva as maintenance therapy for non-small cell lung cancer seems an example of the increasingly specialized and intense nature of drug development: the panel wanted bigger, larger studies with more subgroup analyses